Abstract:DNA methylation is a fundamental modification characterized by the addition of a methyl group to the cytosine bases of DNA and plays an important role in regulating gene expression, maintaining genome stability, and influencing cellular differentiation. Since the identification of abnormal DNA methylation in primary human tumors, comprehensive research has been conducted and strongly demonstrates that distorted DNA methylation patterns in cancer can lead to the silencing of inhibitory genes and the activation of oncogenes, thereby promoting tumorigenesis, progression, and resistance to treatment. These alterations in the methylation landscape present both challenges and opportunities for cancer treatment: it cannot only serve as hallmark features of cancer for early detection and monitoring treatment response, but also offer unique insights into potential therapeutic targets and new treatment strategies. The exploration of the molecular mechanisms underlying the changes in DNA methylation levels highlights the intricate relationship between DNA methylation, gene regulation, and cancer pathophysiology, allowing researchers to identify potential therapeutic targets that can effectively and safely inhibit the growth of cancer cells. This research topic aims to explore the complexity of DNA methylation in cancer therapy, highlighting its significance as a biomarker for diagnosis and prognosis, as well as a promising avenue for innovative treatment strategies.Zhang et al., attempted to develop a prognostic model for hepatocellular carcinoma (HCC) based on the expression of DNA methylation-related genes to identify potential therapeutic targets and predict overall survival. The researchers analyzed the transcriptomic, clinical, and DNA methylation data from The Cancer Genome Atlas Liver Hepatocellular Carcinoma database and the GSE54236 liver cancer dataset. They identified three methylation-related differential genes-GLS, MEX3B, and GNA14and established a risk score model to predict patient prognosis. The model was validated using an independent dataset, and its accuracy was further confirmed through qRT-PCR and immunohistochemistry. The study concluded that the gene signature could provide reliable predictions for clinical applications and enhance the understanding of the mechanisms behind the occurrence and progression of HCC.Liu et al., investigated the correlation between TERT promoter methylation and its expression levels in papillary thyroid cancer (PTC). By analyzing 571 PTC samples from The Cancer Genome Atlas (TCGA), the researchers found that patients with TERT hypermethylation had significantly higher expression level and poorer clinical outcomes compared to those with TERT hypomethylation. Additionally, the study demonstrated that treatment with the demethylating agent decitabine reduced TERT expression and cell viability in PTC cell lines. The findings suggest that TERT promoter methylation can serve as a prognostic marker for PTC risk stratification. The research enhances our understanding of the epigenetic mechanisms underlying the progression of PTC and provides a potential target for therapeutic intervention.Peng et al., explored the role of DNA methylation in hepatocellular carcinoma (HCC), focusing on how methylation modifications influence the tumor microenvironment (TME) and the efficacy of immunotherapy. Through a comprehensive analysis of DNA methylation regulators and TME profiles in HCC, the researchers identified three distinct methylation patterns, each with unique TME characteristics. They developed a DNA methylation score (DMscore) to evaluate individual methylation levels, which could predict patient subtype, TME infiltration, and prognosis. A low DMscore, indicative of an inflamed TME with high tumor mutation burden (TMB) and viral infection, was associated with poor survival outcomes. This study suggests that the DMscore can serve as a valuable biomarker for survival and immunotherapy response in HCC patients, potentially aiding in the optimization of immunotherapy approaches.Li et al., investigates the association between MGMT promoter methylation, CD47, and TIGIT expression levels and their impact on patient prognosis in adult diffuse gliomas (ADG). This study reclassified ADG into astrocytoma, oligodendroglioma, and glioblastoma (GBM) based on the 2021 WHO classification system. The findings revealed that higher CD47 and TIGIT expression levels in tumor tissues are associated with poorer overall survival rates. Notably, MGMT unmethylation is linked to a poor prognosis in astrocytoma patients. The study suggests that patients with elevated CD47 and TIGIT expression may benefit from anti-CD47 and TIGIT immunotherapy, highlighting the potential of these markers for therapeutic intervention in ADG. However, due to the unbalanced sample size of ADG subtypes and the lack of treated patients, this study acknowledges limitations which p -Abstract Truncated-

Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy

The Methylation Modification of M6a Regulators Contributes to the Prognosis of Head and Neck Squamous Cell Carcinoma

Epigenetics in the diagnosis and prognosis of head and neck cancer: A systematic review

DNA Methylation as a Diagnostic, Prognostic, and Predictive Biomarker in Head and Neck Cancer

An aberrant DNA methylation signature for predicting the prognosis of head and neck squamous cell carcinoma

Global DNA Methylation Level in Whole Blood as a Biomarker in Head and Neck Squamous Cell Carcinoma

Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma

Identification of M6a Methyltransferase-Related Genes Predicts Prognosis and Immune Infiltrates in Head and Neck Squamous Cell Carcinoma

Identification and Analysis of DNA Methylation-Driven Signatures for Prognostic and Immune Microenvironments Evaluation in Hepatocellular Carcinoma

Genomic Profiling of a Clinically Annotated Cohort of Locoregionally Advanced Head and Neck Cancers (HNC) Treated with Definitive Chemoradiotherapy.

DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma

Integrated analysis of methylation and transcriptome identifies a novel risk model for diagnosis, prognosis, and immune characteristics in head and neck squamous cell carcinoma

Editorial: DNA methylation in cancer therapy: therapeutic targets and molecular mechanism

Methylation related genes are associated with prognosis of patients with head and neck squamous cell carcinoma via altering tumor immune microenvironment

SP1 Gene Methylation in Head and Neck Squamous Cell Cancer in HPV-Negative Patients

The Interplay of HIF1A, DNA Methylation, and Prolyl Hydroxylases in Head and Neck Squamous Cell Carcinoma

Analysis of methylation-driven genes for predicting the prognosis of patients with oral squamous cell carcinoma

Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitors

New Dna Methylation Markers and Global Dna Hypomethylation Are Associated with Oral Cancer Development

Integrated Data Analysis Implicates PLAU, SERPINE1, SPP1, and MMP1 As Prognostic Factors in Head and Neck Squamous Cell Carcinoma

Progress in Precision Medicine for Head and Neck Cancer